EMA Recommends a Change to the Terms of the Marketing Authorisation for Trametinib
EMA adopts an extension to the existing indication
On 23 July 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product trametinib (Mekinist).
The marketing authorisation holder for this medicinal product is Novartis Europharm Ltd.
The CHMP adopted an extension to the existing indication as follows:
“Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy.”
Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.